Bausch + Lomb plans Ph3 trial for dry eye drop, despite missing mid-stage goal

Phase 2negativeNegative

AI Analysis

Summary

Bausch + Lomb's dual-action dry eye drop failed its Phase 2 study, but the company plans to advance the program to Phase 3 trials despite missing the mid-stage efficacy goal.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Not Met

Outcome Details

Phase 2 study failed to meet mid-stage goal

Importance:6/10

Sentiment:

-0.30

Phase 2 failuredry eyedual-action dropPhase 3 advancement

Related Companies

$BTTX

Read the original article

Published by Endpoints News on August 24, 2026 8:00 PM

Read Original